Valuation: Tenax Therapeutics, Inc.

Market Cap 770M 666M 622M 570M 1.07B 73.27B 1.09B 7.3B 2.86B 36.72B 2.89B 2.83B 121B P/E 2026 *
-9.26x
P/E 2027 * -9.23x
Enterprise Value 685M 593M 553M 508M 955M 65.21B 970M 6.49B 2.55B 32.68B 2.57B 2.52B 108B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.02%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tenax Therapeutics, Inc.

1 day+0.98%
1 week-1.90%
Current month-1.90%
1 month-26.64%
3 months+15.27%
6 months+3.38%
Current year+10.25%
1 week 12.97
Extreme 12.97
14.64
1 month 12.97
Extreme 12.97
17.22
Current year 10.25
Extreme 10.25
19.4
1 year 5.78
Extreme 5.78
19.4
3 years 2.77
Extreme 2.77
61.2
5 years 2.77
Extreme 2.77
3,135.04
10 years 2.77
Extreme 2.77
84,800
Manager TitleAgeSince
Chief Executive Officer 52 14/07/2021
Director of Finance/CFO 58 11/05/2026
Chief Tech/Sci/R&D Officer - 21/01/2025
Director TitleAgeSince
Chairman 67 01/06/2021
Director/Board Member 76 25/02/2021
Director/Board Member 69 25/02/2021
Date Insider Type Main position Quantity % Market Cap.
13/07/26 Fiscal year

Chief Executive Officer

17,438 0.0657%
11/05/26 Free

Chief Financial Officer

460,000 2.6748%
30/01/26 Other

Controller/Auditor

50,000 0.8008%
Change 5-day change 1-year change 3-year change Capi.($)
+0.98%-1.90%+127.41%-45.63% 770M
+0.99%+1.78%+5.07%+16.49% 49.47B
+3.71%+9.40%+486.14%+592.61% 43.97B
+5.60%+10.21%+20.85%+73.63% 39.6B
+2.70%+1.57%+32.71%+9.15% 39.29B
+2.21%+6.75%+20.20%+54.40% 32.43B
+2.23%+4.71% - - 16.84B
+0.97%+2.35%+35.99%+122.50% 16.49B
-0.11%+2.41%+5.03%+20.01% 14.01B
+0.75%+15.04%+79.84%+23.95% 12.77B
Average +2.00%+5.50%+90.36%+96.35% 26.56B
Weighted average by Cap. +2.54%+6.08%+105.20%+138.60%

Financials

2026 *2027 *
Net sales - -
Net income -75.42M -65.24M -60.92M -55.89M -105M -7.18B -107M -715M -281M -3.6B -283M -277M -11.89B -90.17M -78M -72.84M -66.82M -126M -8.58B -128M -855M -335M -4.3B -339M -331M -14.22B
Net Debt -84.7M -73.27M -68.42M -62.76M -118M -8.06B -120M -803M -315M -4.04B -318M -311M -13.36B -8.2M -7.09M -6.62M -6.08M -11.43M -780M -11.61M -77.71M -30.5M -391M -30.79M -30.12M -1.29B
Logo Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Employees
15
Date Price Change Volume
07/08/26 $13.44 +0.98% 2,094,837
06/08/26 $13.31 +1.99% 1,191,903
05/08/26 $13.05 -5.57% 2,250,025
04/08/26 $13.82 -3.56% 2,253,815
03/08/26 $14.33 +4.60% 2,000,706
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
13.44USD
Average target price
35.30USD
Spread / Average Target
+162.65%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TENX Stock